We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Clavis Pharma Announces the Appointment of Athos Gianella-Borradori MD as Chief Medical Officer

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Clavis Pharma Announces the Appointment of Athos Gianella-Borradori MD as Chief Medical Officer"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Clavis Pharma ASA announces the appointment of Athos Gianella-Borradori MD as Chief Medical Officer (CMO). Dr Gianella-Borradori is an experienced onco-hematologist and drug developer, with 30 years experience in the field. He spent the past 20 years in industry, focused on translational research and on the clinical development of novel anti-cancer agents.

During this career, he has held managerial and senior clinical research and development roles at Novartis (Switzerland), Crucell (The Netherlands), Bavarian Nordic (Germany), Cyclacel (United Kingdom) and, for the last five years, at Serono, later at Merck Serono (Switzerland).

Before joining the industry, Dr Gianella-Borradori received his medical degree from the University of Bern (Switzerland). He is board certified in Pediatric Hematology and Oncology and practiced for several years at European and US universities.

Dr Gianella-Borradori’s primary role at Clavis will be to drive the clinical development of, elacytarabine, which is in a Phase III trial for patients with acute myeloid leukaemia (AML), and of CP-4126 in partnership with Clovis Oncology, which is in Phase II for patients with pancreatic cancer. He will also contribute to shape the strategy of Clavis and will play a major role in the future developments of Clavis’ novel cancer drug candidates.

Olav Hellebo, CEO, said: “We are very pleased that Athos will be joining the Clavis team as CMO. We believe his extensive international experience in cancer drug development and clinical experience in oncology and haematology will prove extremely valuable as we progress our existing clinical programmes and expand our exciting pipeline of novel LVT-derived cancer candidates. We believe the improved clinical characteristics of these new drug candidates offer the potential to make a significant difference to the treatment of patients with a range a cancer types.”